Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester)
Acute Myeloid Leukemia
Explore 588 assets in Acute Myeloid Leukemia →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07469046CT.gov VAH vs VA in Newly Diagnosed Elderly AML | — | Not Yet Recruiting | — | — | — |
NCT07507825CT.gov Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) | — | Not Yet Recruiting | — | — | — |
NCT07651176CT.gov Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07651163CT.gov Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07505160CT.gov Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients | — | Not Yet Recruiting | — | — | — |
NCT07172204CT.gov Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT06744556CT.gov HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | — | Active Not Recruiting | — | — | — |
NCT06810791CT.gov HVA vs IA/DA or VA in the Treatment of ND HR-AML | — | Recruiting | — | — | — |
NCT06470841CT.gov CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | — | Not Yet Recruiting | — | — | — |
NCT06529250CT.gov Intermediate-dose HAD Regimen for CEBPA Double-mutated AML | — | Recruiting | — | — | — |
Show 19 more trialsShow fewer
NCT06483906CT.gov Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | — | Recruiting | — | — | — |
NCT06394011CT.gov Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | — | Recruiting | — | — | — |
NCT07437170CT.gov Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | — | Active Not Recruiting | — | — | — |
NCT06221683CT.gov Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | — | Recruiting | — | — | — |
NCT05941585CT.gov Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05805098CT.gov Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | — | Recruiting | — | — | — |
NCT05726110CT.gov Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05457361CT.gov VAH Versus VA for Salvage Therapy of R/R-AML | — | Unknown | — | — | — |
NCT04874194CT.gov Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | — | Terminated | — | — | — |
NCT05029141CT.gov New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04415008CT.gov Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04248595CT.gov Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | — | Unknown | — | — | — |
NCT04087967CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | — | Unknown | — | — | — |
NCT04083911CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | — | Unknown | — | — | — |
NCT03135054CT.gov Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD | — | Unknown | — | — | — |
NCT03170895CT.gov Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | — | Completed | — | — | — |
NCT02440568CT.gov AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | — | Terminated | — | — | — |
NCT01873495CT.gov Omacetaxine for Consolidation and Maintenance | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) (this asset) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | P3 | B · 59 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leukemia | — | P2 | B · 58 |
| Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication | — | P2 | B · 57 |
| Childhood Acute Lymphoblastic Leukemia | — | P2/3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cephalotaxine-4-methyl-2r-2-hydroxy-2-4-hydroxy-4-methylpentylbutanedioate-ester-acute-myeloid-leukemia-104434
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →